Antibody evasion by the P.1 strain of SARS-CoV-2

Antibody evasion by the P.1 strain of SARS-CoV-2

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates. However, new strains have emerged with multiple mutations, including P.1 from Brazil, B.1.351 from South Africa, and B.1.1.7...

Descripció completa

Dades bibliogràfiques
Autors principals:	Dejnirattisai, W, Zhou, D, Supasa, P, Liu, C, Mentzer, AJ, Ginn, HM, Zhao, Y, Duyvesteyn, HME, Tuekprakhon, A, Nutalai, R, Wang, B, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Levin, R, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Paterson, NG, Williams, MA, Hall, DR, Hulswit, RJG, Bowden, TA, Fry, EE, Mongkolsapaya, J, Ren, J, Stuart, DI, Screaton, GR
Format:	Journal article
Idioma:	English
Publicat:	Cell Press 2021

Ítems similars

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
per: Zhou, D, et al.
Publicat: (2021)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
per: Liu, C, et al.
Publicat: (2021)

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
per: Supasa, P, et al.
Publicat: (2021)

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
per: Nutalai, R, et al.
Publicat: (2022)

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
per: Liu, C, et al.
Publicat: (2021)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
per: Dejnirattisai, W, et al.
Publicat: (2022)

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
per: Tuekprakhon, A, et al.
Publicat: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
per: Huo, J, et al.
Publicat: (2022)

Integrative structural biology of viruses
per: Duyvesteyn, HME
Publicat: (2019)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
per: Dejnirattisai, W, et al.
Publicat: (2021)

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
per: Daming Zhou, et al.
Publicat: (2024-03-01)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
per: Aiste Dijokaite-Guraliuc, et al.
Publicat: (2022-11-01)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
per: Flaxman, A, et al.
Publicat: (2021)

The alteration of NK cells phenotypes related to the functions and dengue disease outcomes
per: Napas Taechasan, et al.
Publicat: (2024-07-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
per: Watanabe, Y, et al.
Publicat: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
per: Ragonnet-Cronin, M, et al.
Publicat: (2023)

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
per: McNaughton, AL, et al.
Publicat: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
per: Marchevsky, NG, et al.
Publicat: (2022)

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
per: Peng, Y, et al.
Publicat: (2020)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
per: Yasunori Watanabe, et al.
Publicat: (2021-04-01)

Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus
per: Renner, M, et al.
Publicat: (2018)

Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection
per: Fernandez, E, et al.
Publicat: (2017)

The antigenic anatomy of SARS-CoV-2 receptor binding domain
per: Dejnirattisai, W, et al.
Publicat: (2021)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
per: Jiandong Huo, et al.
Publicat: (2022-11-01)

Evolution of neurovirulent Zika virus
per: Screaton, G, et al.
Publicat: (2017)

Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
per: Screaton, G, et al.
Publicat: (2018)

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
per: Townsend, A, et al.
Publicat: (2021)

The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world
per: Sharpe, HR, et al.
Publicat: (2020)

Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen
per: Sheerin, D, et al.
Publicat: (2021)

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
per: Manon Ragonnet-Cronin, et al.
Publicat: (2023-06-01)

Accelerating drug target inhibitor discovery with a deep generative foundation model
per: Chenthamarakshan, V, et al.
Publicat: (2023)

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
per: Faria, NR, et al.
Publicat: (2021)

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.
per: Midgley, C, et al.
Publicat: (2012)

Sensing of immature particles produced by dengue virus infected cells induces an antiviral response by plasmacytoid dendritic cells.
per: Elodie Décembre, et al.
Publicat: (2014-10-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
per: Folegatti, PM, et al.
Publicat: (2020)

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
per: Chang Liu, et al.
Publicat: (2024-04-01)

Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope
per: Alexander Rouvinski, et al.
Publicat: (2017-05-01)

Humidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virus.
per: Chotiyarnwong, P, et al.
Publicat: (2007)

Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine
per: Tsai, W, et al.
Publicat: (2018)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
per: Voysey, M, et al.
Publicat: (2023)